Patients / advocates

Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate

Alzheimer’s Trials Are Finally Blood-Gated

MS Regulators Are No Longer Reading the Same Risk

NTDs Are Now A Human-Rights Issue. Budgets Must Follow.

Europe Can Forecast Vibrio Risk. It Still Has To Act.

Cardiology has too many dashboards. The danger is forgetting the patient

GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up

A CE Mark Is Not Access

Europe Opens the SMA Gene-Therapy Door Wider
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
